Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program
Abstract
:Simple Summary
Abstract
1. Background
2. Materials and Methods
2.1. Study Design and Ethics
2.2. Patients
2.3. PIPAC Procedure
2.4. Study Outcomes
2.5. Statistical Analysis
3. Results
3.1. Baseline Characteristics
3.2. PIPAC Procedure Characteristics
3.3. Long Term Outcomes
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Ellebæk, S.B.; Graversen, M.; Detlefsen, S.; Lundell, L.; Fristrup, C.W.; Pfeiffer, P.; Mortensen, M.B. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) of Peritoneal Metastasis from Gastric Cancer: A Descriptive Cohort Study. Clin. Exp. Metastasis 2020, 37, 325–332. [Google Scholar] [CrossRef] [PubMed]
- Maconi, G.; Manes, G.; Porro, G.B. Role of Symptoms in Diagnosis and Outcome of Gastric Cancer. World J. Gastroenterol. 2008, 14, 1149–1155. [Google Scholar] [CrossRef]
- Manzanedo, I.; Pereira, F.; Pérez-Viejo, E.; Serrano, Á. Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment. Cancers 2023, 15, 1777. [Google Scholar] [CrossRef] [PubMed]
- Reutovich, M.Y.; Krasko, O.V.; Sukonko, O.G. Hyperthermic Intraperitoneal Chemotherapy in Prevention of Gastric Cancer Metachronous Peritoneal Metastases: A Systematic Review. J. Gastrointest. Oncol. 2021, 12, S5. [Google Scholar] [CrossRef] [PubMed]
- Luksta, M.; Bausys, A.; Bickaite, K.; Rackauskas, R.; Paskonis, M.; Luksaite-Lukste, R.; Ranceva, A.; Stulpinas, R.; Brasiuniene, B.; Baltruskeviciene, E.; et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Cisplatin and Doxorubicin in Combination with FOLFOX Chemotherapy as a First-Line Treatment for Gastric Cancer Patients with Peritoneal Metastases: Single-Arm Phase II Study. BMC Cancer 2023, 23, 1032. [Google Scholar] [CrossRef]
- Sun, B.J.; Lee, B. Review of Regional Therapies for Gastric Cancer with Peritoneal Metastases. Cancers 2022, 14, 570. [Google Scholar] [CrossRef]
- Rau, B.; Brandl, A.; Piso, P.; Pelz, J.; Busch, P.; Demtröder, C.; Schüle, S.; Schlitt, H.-J.; Roitman, M.; Tepel, J.; et al. Peritoneal Metastasis in Gastric Cancer: Results from the German Database. Gastric Cancer 2020, 23, 11–22. [Google Scholar] [CrossRef]
- Dong, Y.; Tu, Y.; Liu, Y.; Jiang, M.; Bulatov, E.; Yuan, Y.; Wang, J. Perivascular Nanocarrier Aggregation as a Drug Reservoir Augments Tumor Drug Delivery and Treatment Efficacy. Nano. Today 2023, 53, 102004. [Google Scholar] [CrossRef]
- Christou, N.; Auger, C.; Battu, S.; Lalloué, F.; Jauberteau-Marchan, M.-O.; Hervieu, C.; Verdier, M.; Mathonnet, M. Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives. Biology 2021, 10, 225. [Google Scholar] [CrossRef]
- Brandl, A.; Prabhu, A. Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Peritoneal Metastases: An Overview of Common Therapeutic Regimens. J. Gastrointest. Oncol. 2021, 12, S32–S44. [Google Scholar] [CrossRef]
- Badgwell, B.; Blum, M.; Das, P.; Estrella, J.; Wang, X.; Ho, L.; Fournier, K.; Royal, R.; Mansfield, P.; Ajani, J. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann. Surg. Oncol. 2017, 24, 3338–3344. [Google Scholar] [CrossRef] [PubMed]
- Račkauskas, R.; Baušys, A.; Lukšta, M.; Jurgaitis, J.; Paškonis, M.; Strupas, K. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Malignancy: Initial Experience of the First Program in the Baltic Countries. World J. Surg. Oncol. 2021, 19, 236. [Google Scholar] [CrossRef] [PubMed]
- Case, A.; Prosser, S.; Peters, C.J.; Adams, R.; Gwynne, S. Pressurised Intraperitoneal Aerosolised Chemotherapy (PIPAC) for Gastric Cancer with Peritoneal Metastases: A Systematic Review by the PIPAC UK Collaborative. Crit. Rev. Oncol. Hematol. 2022, 180, 103846. [Google Scholar] [CrossRef] [PubMed]
- Solass, W.; Sempoux, C.; Detlefsen, S.; Carr, N.J.; Bibeau, F. Peritoneal Sampling and Histological Assessment of Therapeutic Response in Peritoneal Metastasis: Proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum 2016, 1, 99–107. [Google Scholar] [CrossRef]
- Struller, F.; Horvath, P.; Solass, W.; Weinreich, F.-J.; Strumberg, D.; Kokkalis, M.K.; Fischer, I.; Meisner, C.; Königsrainer, A.; Reymond, M.A. Pressurized Intraperitoneal Aerosol Chemotherapy with Low-Dose Cisplatin and Doxorubicin (PIPAC C/D) in Patients with Gastric Cancer and Peritoneal Metastasis: A Phase II Study. Ther. Adv. Med. Oncol. 2019, 11, 1758835919846402. [Google Scholar] [CrossRef]
- Khomyakov, V.; Ryabov, A.; Ivanov, A.; Bolotina, L.; Utkina, A.; Volchenko, N.; Kaprin, A. Bidirectional Chemotherapy in Gastric Cancer with Peritoneal Metastasis Combining Intravenous XELOX with Intraperitoneal Chemotherapy with Low-Dose Cisplatin and Doxorubicin Administered as a Pressurized Aerosol: An Open-Label, Phase-2 Study (PIPAC-GA2). Pleura Peritoneum 2016, 1, 159–166. [Google Scholar] [CrossRef] [PubMed]
- Sindayigaya, R.; Dogan, C.; Demtröder, C.R.; Fischer, B.; Karam, E.; Buggisch, J.R.; Tempfer, C.B.; Lecomte, T.; Ouaissi, M.; Giger-Pabst, U. Clinical Outcome for Patients Managed with Low-Dose Cisplatin and Doxorubicin Delivered as Pressurized Intraperitoneal Aerosol Chemotherapy for Unresectable Peritoneal Metastases of Gastric Cancer. Ann. Surg. Oncol. 2022, 29, 112–123. [Google Scholar] [CrossRef]
- Di Giorgio, A.; Schena, C.A.; El Halabieh, M.A.; Abatini, C.; Vita, E.; Strippoli, A.; Inzani, F.; Rodolfino, E.; Romanò, B.; Pacelli, F.; et al. Systemic Chemotherapy and Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A Bidirectional Approach for Gastric Cancer Peritoneal Metastasis. Surg. Oncol. 2020, 34, 270–275. [Google Scholar] [CrossRef]
- Gockel, I.; Jansen-Winkeln, B.; Haase, L.; Rhode, P.; Mehdorn, M.; Niebisch, S.; Moulla, Y.; Lyros, O.; Lordick, F.; Schierle, K.; et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study. J. Gastric Cancer 2018, 18, 379–391. [Google Scholar] [CrossRef]
- Becker, K.; Mueller, J.D.; Schulmacher, C.; Ott, K.; Fink, U.; Busch, R.; Böttcher, K.; Siewert, J.R.; Höfler, H. Histomorphology and Grading of Regression in Gastric Carcinoma Treated with Neoadjuvant Chemotherapy. Cancer 2003, 98, 1521–1530. [Google Scholar] [CrossRef]
- Baake, J.; Nadiradze, G.; Archid, R.; Königsrainer, A.; Bösmüller, H.; Reymond, M.; Solass, W. Peritoneal Regression Grading Score (PRGS): First Evidence for Independent Predictive and Prognostic Significance. Pleura Peritoneum 2023, 8, 55–63. [Google Scholar] [CrossRef] [PubMed]
- De Simone, M.; Vaira, M.; Argenziano, M.; Berchialla, P.; Pisacane, A.; Cinquegrana, A.; Cavalli, R.; Borsano, A.; Robella, M. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial. Biomedicines 2020, 8, 102. [Google Scholar] [CrossRef] [PubMed]
- Sgarbura, O.; Hübner, M.; Alyami, M.; Eveno, C.; Gagnière, J.; Pache, B.; Pocard, M.; Bakrin, N.; Quénet, F. Oxaliplatin Use in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Is Safe and Effective: A Multicenter Study. Eur. J. Surg. Oncol. 2019, 45, 2386–2391. [Google Scholar] [CrossRef] [PubMed]
- Willaert, W.; de Sande, L.V.; Daele, E.V.; Putte, D.V.D.; Nieuwenhove, Y.V.; Pattyn, P.; Ceelen, W. Safety and Preliminary Efficacy of Electrostatic Precipitation during Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Unresectable Carcinomatosis. Eur. J. Surg. Oncol. 2019, 45, 2302–2309. [Google Scholar] [CrossRef]
- Alyami, M.; Bonnot, P.-E.; Mercier, F.; Laplace, N.; Villeneuve, L.; Passot, G.; Bakrin, N.; Kepenekian, V.; Glehen, O. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Unresectable Peritoneal Metastasis from Gastric Cancer. Eur. J. Surg. Oncol. 2020, 47, 123–127. [Google Scholar] [CrossRef]
- Tidadini, F.; Abba, J.; Quesada, J.-L.; Baudrant, M.; Bonne, A.; Foote, A.; Faucheron, J.-L.; Glehen, O.; Villeneuve, L.; Arvieux, C. Effect of Pressurized Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients with Peritoneal Carcinomatosis of Gastric Origin. J. Gastrointest. Canc. 2022, 53, 971–979. [Google Scholar] [CrossRef]
- Feldbrügge, L.; Gronau, F.; Brandl, A.; Auer, T.A.; Oeff, A.; Thuss-Patience, P.; Pratschke, J.; Rau, B. Systemic Chemotherapy Including Ramucirumab in Combination with Pressurized Intra-Peritoneal Aerosol Chemotherapy Is a Safe Treatment Option for Peritoneal Metastasis of Gastric Cancer. Front. Oncol. 2021, 10, 610572. [Google Scholar] [CrossRef]
- Kurtz, F.; Struller, F.; Horvath, P.; Solass, W.; Bösmüller, H.; Königsrainer, A.; Reymond, M.A. Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study. Gastroenterol. Res. Pract. 2018, 2018, 2743985. [Google Scholar] [CrossRef]
- Alyami, M.; Mercier, F.; Siebert, M.; Bonnot, P.-E.; Laplace, N.; Villeneuve, L.; Passot, G.; Glehen, O.; Bakrin, N.; Kepenekian, V. Unresectable Peritoneal Metastasis Treated by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Leading to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Eur. J. Surg. Oncol. 2021, 47, 128–133. [Google Scholar] [CrossRef]
Sex, n (%) | Female | 15 (46.9%) |
---|---|---|
Male | 17 (53.1%) | |
Median age (Q1; Q3), years | 55 (46; 66) | |
Median hospitalization (Q1; Q3), days | 2 (1; 4.3) | |
Median BMI (Q1; Q3) | 22.7 (20.3; 25.1) | |
History of radical surgery for primary tumor, n (%) | Yes | 5 (15.6%) |
No | 27 (84.4%) | |
Median CEA level (Q1; Q3) at the time of first PIPAC, ng/L | 1.9 (0.98; 5) | |
Median CA19.9 level (Q1; Q3) at the time of first PIPAC, ng/L | 12.8 (3.6; 77.1) | |
Number of PIPAC procedures, n (%) | 1 | 9 (28.1%) |
2 | 9 (28.1%) | |
3 | 13 (40.6%) | |
5 | 1 (3.1%) | |
Median operation time (Q1; Q3), min | 92.5 (85; 110) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Luksta, M.; Bausys, A.; Gendvilaite, N.; Bickaite, K.; Rackauskas, R.; Paskonis, M.; Luksaite-Lukste, R.; Ranceva, A.; Stulpinas, R.; Brasiuniene, B.; et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program. Cancers 2024, 16, 2992. https://doi.org/10.3390/cancers16172992
Luksta M, Bausys A, Gendvilaite N, Bickaite K, Rackauskas R, Paskonis M, Luksaite-Lukste R, Ranceva A, Stulpinas R, Brasiuniene B, et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program. Cancers. 2024; 16(17):2992. https://doi.org/10.3390/cancers16172992
Chicago/Turabian StyleLuksta, Martynas, Augustinas Bausys, Neda Gendvilaite, Klaudija Bickaite, Rokas Rackauskas, Marius Paskonis, Raminta Luksaite-Lukste, Anastasija Ranceva, Rokas Stulpinas, Birute Brasiuniene, and et al. 2024. "Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program" Cancers 16, no. 17: 2992. https://doi.org/10.3390/cancers16172992